Derivatives of phenyl - and aminobenzenesulfonamide and pharmaceutical composition based on them

 

The invention relates to new derivatives of phenyl - and aminobenzenesulfonamide formulawhere a denotes (R1SO2NR2-), (R3R60NSO2NR2-); X represents-NH-, -CH2- or-OCH2-; Y represents 2-imidazoline, 2-oxazoline or 4-imidazole; R1means (NISS. )alkyl or phenyl; R2, R3and R60each independently of one another denotes hydrogen, (NISS. )alkyl or phenyl; R4, R5, R6and R7each independently of one another denotes hydrogen, (ness.)alkyl, -CF3, (NISS. )alkoxygroup, halogen, phenyl, (ness.)alkenyl, hydroxyl, (NISS. )alkylsulfonate or (ness.)- cycloalkyl, where R2and R7together can optionally form alkylene or albaniles with 2-3 carbon atoms in the unsubstituted or optionally substituted 5 - or 6-membered ring, where the optional substituents of the ring include halogen atoms, (ness.)alkali or CN, provided that when R7denotes hydroxyl or (NISS. )alkylsulfonate, X means-NH-, wherein Y denotes a 2-imidazolin; or their pharmaceutically acceptable salts, and pharmaceutical compositions based on them, intended for regulators. The technical result - obtaining new biologically active compounds and drugs based on them for use in medicine. 2 C. and 14 C.p. f-crystals, 5 PL.

Description text in facsimile form (see graphic part). T T TC

Claims

1. Derivatives of phenyl - and aminobenzenesulfonamide formulas

where a denotes (R1SO2NR2-), (RCR60NSO2NR2-);

X represents-NH-, -CH2- or-och2-;

Y denotes a 2-imidazoline, 2-oxazoline or 4-imidazole;

R1means (ness.)alkyl or phenyl;

R2, R3and R60each independently of one another denotes hydrogen, (ness.)alkyl or phenyl;

R4, R5, R6and R7each independently of one another denotes hydrogen, (ness.)alkyl, -CF3, (ness.)alkoxygroup, halogen, phenyl, (ness.)alkenyl, hydroxyl, (ness.)alkylsulfonate or (ness.)-cycloalkyl, where R2and R7together can optionally form alkylene or albaniles with 2-3 carbon atoms in the unsubstituted or optionally substituted 5 - or 6-membered ring, where the optional substituents for the ZS.)alkylsulfonate, X represents-NH-, wherein Y denotes a 2-imidazolin,

or its pharmaceutically acceptable salt.

2. Connection on p. 1 formula

where Xadenotes-NH-, -CH2- or-och2-;

Yadenotes 2-imidazoline, 2-oxazoline or 4-imidazole;

R8means (ness.)alkyl, phenyl or NR14R15;

R9, R14and R15each independently of the other represents H or (ness.)alkyl;

R10, R11, R12and R13each independently of one another denotes hydrogen, lower alkyl, -CF3, lower alkoxygroup, halogen, phenyl, lower alkenyl, hydroxyl, (ness.)alkylsulfonate or (ness.)cycloalkyl,

R9and R13together may not necessarily form alkylene or albaniles with 2-3 carbon atoms in the 5 - or 6-membered ring, provided that when R13denotes hydroxyl or (ness.)alkylsulfonate and Y3denotes 2-imidazolin, Xanot means-NH-,

or its pharmaceutically acceptable salt.

3. The compound according to any one of paragraphs.1 and 2 formulas

where Ybdenotes 2-imidazolin;

R16means (ness.) alkyl;

R17represents H or (the bottom of the sh.)alkyl, -CF3, (ness.) alkoxygroup or halogen,

or its pharmaceutically acceptable salt.

4. The compound according to any one of paragraphs. 1-3 formulas

where Ybdenotes 2-imidazolin;

R16means (ness.)alkyl;

R34, R35and R36each independently of one another denotes H, CL, Br, F or (ness.)alkyl,

or its pharmaceutically acceptable salt.

5. Connection PP. 1 and 2 formulas

where Ycdenotes 2-imidazoline or 4-imidazole;

R22means (ness.)alkyl;

R23represents H or (ness.)alkyl;

R24, R25, R26and R27each independently of one another denotes hydrogen, (ness.)alkyl, (ness.)alkoxygroup, halogen, phenyl, (ness.)alkenyl, hydroxyl or (ness.)alkylsulfonate,

or its pharmaceutically acceptable salt.

6. Connection on p. 5 formulas

where Ycdenotes 2-imidazoline or 4-imidazole;

R22means (ness.)alkyl;

R34, R35and R36each independently of one another denotes H, Cl, Br, F or (ness.)alkyl, or its pharmaceutically acceptable salt.

7. The compound according to any one of paragraphs.1 and 2 formulas

em (ness.)alkyl or phenyl;

R29independently represents hydrogen, lower alkyl or phenyl;

R30, R31, R32and R33each independently of one another denotes hydrogen, (ness.)alkyl, halogen, hydroxyl or (ness.)cycloalkyl,

or its pharmaceutically acceptable salt.

8. Connection on p. 7 formulas

where Yddenotes 2-imidazoline or 4-imidazole; R28means (ness.)alkyl;

R34, R35and R36each independently of one another denotes H, Cl, Br, F or (ness.)alkyl,

or its pharmaceutically acceptable salt.

9. The compound according to any one of paragraphs.1 and 2 formulas,

where Xgdenotes-NH-, -CH2- or-och2-;

Ygdenotes 2-imidazoline, 2-oxazoline or 4-imidazole;

R55means (ness.)alkyl or phenyl;

R56forms part unsubstituted or optionally substituted 5 - or 6-membered ring, where the optional substituents in the ring are halo, (ness.)alkyl or-CN, and R56means (CH2)kwhere k = 2 or 3, CH=CH, CH=SNSN2or CH2SN=SN;

R57, R58and R59each independently of one another denotes hydrogen, (ness.)alkyl, -CFKill,

or its pharmaceutically acceptable salt.

10. Connection on p. 1 or 2 formulas

where Xfdenotes-NH-, -CH2- or-och2-; Yfdenotes 2-oxazoline;

R48means (ness.)alkyl;

R49represents H or (ness.)alkyl;

R50, R51, R52and R53each independently of one another denotes hydrogen, (ness.)alkyl, -CF3, (ness.)alkoxygroup, halogen, phenyl, (ness.)alkenyl, hydroxyl, (ness.)alkylsulfonate or (ness.)cycloalkyl,

R49and R53together may not necessarily form alkylene or albaniles with 2-3 carbon atoms in the 5 - or 6-membered ring,

or its pharmaceutically acceptable salt.

11. Connection on p. 1 or 2 formulas

where Xedenotes-NH-, -CH2- or-och2-;

Yedenotes 2-imidazoline, 2-oxazoline or 4-imidazole;

R41, R42and R43each independently of the other represents H, phenyl or (ness.)alkyl;

R44, R45, R46and R47each independently of one another denotes hydrogen, (ness.)alkyl, -CF3, (ness.)alkoxygroup, halogen, phenyl, (ness.)alkenyl, hydroxyl, (ness.)alkylsulfate is or albaniles with 2-3 carbon atoms in the 5 - or 6-membered ring,

or its pharmaceutically acceptable salt.

12. The compound according to any one of paragraphs.1-11, selected from the group including

{N-[3-(4,5-dihydro-1H-imidazol-2-ylethoxy)phenyl]methanesulfonamide};

{N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylethoxy)-2-were] methanesulfonamido};

{N-[6-bromo-3-(4,5-dihydro-1H-imidazol-2-ylethoxy)-2-were] methanesulfonamido};

N-[5-(4,5-dihydro-1H-imidazol-2-ylethoxy)-2-forfinal]methanesulfonamide;

N-[3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-were]methanesulfonamide;

N-[3-(imidazolidin-2-ylideneamino)-2-were]methanesulfonamide;

N-[5-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2-were]methanesulfonamide;

N-[2-fluoro-5-(1H-imidazol-4(5)-ylethoxy)phenyl]methanesulfonamide;

the hydrochloride of N,N-dimethyl-N’-[3-(4,5-dihydro-1H-imidazol-2-helmet-hydroxy)phenyl]sulphonamide;

(3-chloro-1-methanesulfonyl-1H-Ivdel-6-yl)imidazolidin-2-ylideneamino or its pharmaceutically acceptable salt.

13. Connection on p. 1, selected from the group including

where X is-CH2- or-och2-;

values of R1, R4, R5R and R7specified in paragraph 1 of the claims

where X is-CH2-;

values of R1, R4, R-CH2- or-och2-;

values of R4, R5, R6and R7specified in paragraph 1 of the claims

where the values of R1, R4, R5, R6and R7specified in paragraph 1 of the claims

where the values of R1, R4, R5and R6specified in paragraph 1 of the claims

where the values of R1, R4, R5and R6specified in paragraph 1 of the claims

where the values of R1, R4, R5and R6specified in paragraph 1 of the claims

where the values of R1, R4, R5, R6and R7specified in paragraph 1 of the claims

where X is-CH2- or-och2-;

values of R1R4, R5, R6and R7specified in paragraph 1 of the claims.

14. The compound according to any one of paragraphs.1-13, with affinity to the alpha1A/1L-adrenergic receptors.

15. The compound according to any one of paragraphs.1-13, intended for the preparation of drugs for the prevention and/or treatment of a pathological state, which improves the treatment of washes the Chennai to regulate physiological phenomena, related substances with affinity for alpha1A/1L-adrenergic receptors, comprising a therapeutically effective amount of a compound according to any one of paragraphs.1-13 in combination with a therapeutically inert carrier.

Priority PM.3, 4, 5, 6, 7, 9, 11 and 12 from 23.06.1997.

Priority PP.1, 2, 8 and 10 from 25.02.1998.

Priority PP.13-16 by date of filing.

 

Same patents:

The invention relates to compounds of formula (1), where X and Y Is N or O; R1substituted alkyl, substituted arylalkyl or cycloalkyl; R2and R3Is h or alkyl; And a Is-C(O)-, -OC(O)-, -S(O)2-; R4- alkyl, cycloalkyl or (C5-C12)aryl; compounds of the formula (2), where X and Y are O, S or N; R1- alkyl, optionally substituted arylalkyl; R2and R3Is h or alkyl;- C(O)-; R6- Deputy, including the condensed heterocyclic rings; and compounds of the formula (3), where X and Y are O, S or N; R1- alkyl, alkylsilane, (C5-C12)arylalkyl, (C5-C12)aryl; R2and R3Is h or alkyl; R2' and R3' - N; R11, R12and E together form a mono - or bicyclic ring which may contain heteroatoms

The invention relates to new derivatives oksiminoalkil acid of the formula (I), where R1is oxazolyl, optionally substituted with 1-2 substituents selected from lower alkyl, phenyl, teinila, furil; thiazolyl, optionally substituted with 1-2 substituents selected from lower alkyl, phenyl; unsubstituted chinoline and so on; X represents a bond or the group-NR6- where R6represents hydrogen or C1-4alkyl; n represents an integer from 1 to 3; Y represents an oxygen atom or the group-NR7- where R7is hydrogen; ring a represents a benzene ring, optionally substituted by one or two1-4alkoxy; p is an integer from 1 to 3; R2represents phenyl, optionally substituted lower alkyl, halogen, and so on; unsubstituted furyl; unsubstituted pyridyl; pyridinyl-1-oxide; q is an integer from 0 to 6; m represents 0 or 1; R3represents a hydroxy-group, lower alkoxy or-NR9R10where R9and R10represent identical or different groups selected from hydrogen, lower alkyl and lower alkylsulfonyl; R4and R5represent identical or different groups selected from hydrogen or

The invention relates to new cyclic diamine compounds of the formula I, where

< / BR>
represents an optionally substituted divalent residue of benzene, where the substituents are selected from unsubstituted lower alkyl groups, unsubstituted lower alkoxygroup, unsubstituted lower acyl group, a lower allylthiourea, lower alkylsulfonyl group, halogen atom, etc. or unsubstituted pyridine; Ar represents a phenyl group which may be substituted by one to four groups selected from unsubstituted lower alkyl group, the unsubstituted alkoxygroup, low allylthiourea, lower alkylsulfonyl group, and so on, optional substituted amino group, alkylenedioxy; X is-NH-, oxygen atom or sulfur atom; Y is a sulfur atom, sulfoxide or sulfon; Z represents a single bond or-NR2-; R2- the atom of hydrogen or unsubstituted lower alkyl group; l = 2 or 3; m = 2 or 3; n = 1, 2, or 3, or their salts, or their solvate

The invention relates to a derivative of benzamidine formula I, where R1denotes-C(=NH)-NH2; R2denotes H; R3refers to -[C(R5)2]m-СООR5, R3and X together represent well-CO-N-, form a 5-membered ring, with R3refers to - C = O, and X denotes N, R4means And, cycloalkyl, -[C(R5)2]mAr; X represents O, NR5or CH2Y represents O, NR5N[C(R5)2]m-Ar, N[C(R5)2]m-Het, - N[C(R5)2]m-СООR5W represents a bond, -SO2-, -CO - or-СОNR5-

The invention relates to substituted 3-cyanohydrins formula (1), where R1, R2, R3, R4, Y and X are such as defined in the claims

The invention relates to 2-(iminomethyl)aminoaniline derivative of General formula I, And where the aromatic residue of the formula Ia, R1and R2independently H, halogen, HE, linear or branched C1-C6alkyl, linear or branched C1-C6alkoxyl, R3-H, linear or branched C1-C6alkyl, or-COR4where R4-C1-C6alkyl or the residue IC, linear or branched C1-C6the five-membered alkyl or a heterocycle containing 1-4 heteroatoms selected from O, S, N, and in particular: thiophene, furan, pyrrole or thiazole, carbon atoms which is unsubstituted or substituted by one or more groups selected from linear or branched C1-C6of alkyl, C1-C6alkoxyl or halogen; X is-CO-N(R3)-X'-, -NH-CO-X'-, -CH=,-CO -, or a bond, and X' represents -(CH2)n- where n = 0-6; Y means Y'-, -Y'-NH-CO-, -CO-Y', Y'-CO-, -N(R3)-Y'-, -Y,-N(R3)-, Y'-CH2-N(R3)-CO-, -Y'-O-, -Y'-O-Y' - or a bond, and Y' is -(CH2)n- where n = 0-6; Неt-pyrrole, pyrrolidine, furan, thiophene, imidazole, imidazoline, oxazole, isoxazol, oxazoline, isoxazole, thiazole, thiazoline, thiazolidine, thiazolidine, azetidine, piperidine, imidazolidine, they

The invention relates to a new derivative of solidilin formula (I) where one of X, Y and Z represents C=O or C=S, and one of the remaining X, Y and Z denotes a group With=, and the other group C=S; R1, R2and R3are Deputy or X, Y and Z, or nitrogen atom and may be the same or different and denote hydrogen, halogen, hydroxy, nitro, etc., the group -(CH2)n-O - and may be joined through the nitrogen atom, or X, Y, Z, n is 1-4, Ar denotes a phenylene or naftilan, R4denotes hydrogen or forms a bond with group a, And denotes nitrogen or CR5, R5denotes hydrogen, halogen or forms a bond with R4In means O or S, when a is CR5and means that, when a is N, its tautomeric forms, stereoisomers, polymorphic forms, pharmaceutically acceptable salt and solvate

The invention relates to the field of organic chemistry, namely to new derivatives of amides heterylamine butenova acids that have anti-inflammatory activity

The invention relates to 1-(3-heteroaromatic or prop-2-enyl)-4-benzylpiperidine formula (1), where X Is O, NR1, S, or CH2; Y is CH; Z is CH; Y and Z together may denote C= S; R1, R2and R3is hydrogen, R4- fluorine

The invention relates to derivatives of cyclic amines and their use as pharmaceuticals, particularly to a compound represented by the General formula (I), its pharmaceutically acceptable acid additive salts or its pharmaceutically acceptable C1-C6alcaldicios salt, R1-phenyl, C3-8-cycloalkyl, aromatic heterocycle with 1-3 heteroatoms selected from O, S, N, or combinations thereof, and these groups may be condensed with benzene ring or an aromatic heterocyclic group with heteroatoms, selected from O, S or N, or combinations thereof, and may also have different substituents

The invention relates to the compound 5-[4-(4-terbisil)piperidine-1-ylmethyl] -3-(4-hydroxyphenyl)oxazolidin-2-it formula I, its enantiomers and physiologically acceptable salts

The invention relates to a derivative benzofurazan or benzo-2,1,3-thiadiazole of the formula I, in which R1represents oxygen or sulfur, R2and R3independently selected from the group consisting of-CR=, M is =CR4- where R4independently represents R, R8is hydrogen, R5selected from the group consisting of-CR=CR1-, -CR=CX-, -(СRR1)n-, R7selected from the group consisting of -(CRR1)n-, -C(O)-, -CRX-, -CXX1-, R6selected from the group consisting of -(CRR1)m-, -C(O)-, -CRX -, -CXX1-, -S - and-O-

The invention relates to new derivatives of spirobiindane General formula (I), where R1represents a phenyl group which may be optionally substituted by 1-3 substituents selected from halogen atoms, lower alkyl groups, halogenized alkyl groups, lower alkoxygroup, lower alkoxycarbonyl groups, hydroxyl groups, lower aliphatic acylamino, cyano groups, or a 5 - or 6-membered heterocyclic group containing 1-3 oxygen atom, sulfur and/or nitrogen, which may be optionally condensed with a phenyl group; R2represents a phenyl group which is substituted by 1-3 fluorine atoms or chlorine; a represents a carbonyl group; represents a simple bond; D represents an oxygen atom or sulfur; E represents C1-4Allenova group;represents a group of formula (II), where G represents C5-8alonovoa ring, which is substituted by hydroxyl group; Ar represents a phenyl ring; n represents the integer 1 or 2, or a pharmacologically acceptable salt

The invention relates to new derivatives of benzoxazinone General formula (I), where R1means N or carboxyethyl, R2represents hydrogen or alkyl, and R3is a different derivatively of amino acids, dipeptides and hydrazones acid groups, respectively, their conjugates with active substances, such as residues from a number of penicillin

The invention relates to new imidazole derivative of General formula (1), where n1is an integer from 1 to 3, a represents hydrogen, linear or branched C1-C10-alkyl, which may be optionally substituted C3-C7-cycloalkyl or lower alkoxy, or a radical selected from the group shown in the formula of the invention, Y represents a radical selected from the group described in the claims, or to his new pharmaceutically acceptable salts

The invention relates to new imidazole derivative of formula I and II

< / BR>
or

< / BR>
where 1, m, r, s, and t = 0 or 1; n = 1 or 2; provided that when 1 and m = 0, n = 2 Y - SO2or CH2; Z - CR12, NR32SO; NR13, NR36CO., OCONR15, SO2NR14; R1selected from the group consisting of hydrogen, alkyl, or aralkyl, the symbola single or double bond, R7, R8selected from the group consisting of hydrogen, aryl, - CN, halogen, and U-R44group, where U = O and R44and R11selected from the group consisting of hydrogen, alkyl, aralkyl, aryl; R32selected from the group consisting of hydrogen, lower alkyl, unsubstituted or substituted phenyl, and tanila; R9, R10, R12, R13, R14, R15, R36, R57and R58represent hydrogen or lower alkyl; one of R, S and T is CH2or CH(CH2)pQ, where Q denotes NR57R58; where p = 0,1 or 2; provided that when Y is - SO2, R11cannot be hydrogen; its enantiomers, diastereoisomers, pharmaceutically priemel the
Up!